Atlas Trials

Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC

Clinical trial NCT04609540 · UNKNOWN

Trial details

NCT number
NCT04609540
Sponsor
Shandong Cancer Hospital and Institute
Status
UNKNOWN
Study type
OBSERVATIONAL
HER2-positive Breast CancerMetastatic Breast Cancer
Start date
2021-01-01
Primary completion
2021-12-01
Enrollment
200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.